免疫检查点抑制剂相关肺炎危险因素及管理策略的研究进展

近年来，随着免疫检查点抑制剂（immune checkpoint inhibitors,ICIs）在肿瘤治疗中的广泛应用，免疫治疗相关不良反应逐渐引起人们的关注。免疫检查点抑制剂相关肺炎（checkpoint inhibitor pneumonitis,CIP）是相对少见的免疫治疗相关肺毒性，也是引起ICIs相关死亡的重要原因之一。积极探索CIP的相关危险因素，甄别出发生CIP的高危人群，有利于CIP的早期诊断、及时治疗。故本文就CIP的危险因素及管理策略研究进展进行综述，以提高临床医生对该不良反应的认识。

Advances in risk factors and management strategies of checkpoint inhibitor pneumonitis

In recent years,with the wide application of immune checkpoint inhibitors in tumor treatment,immune-related adverse events have gradually attracted people's attention.Checkpoint inhibitor pneumonitis(CIP)is a relatively rare immunotherapy related pulmonary toxicity and one of the important causes of immune checkpoint inhibitor related death.Actively explore the relevant risk factors of CIP and identify the high-risk groups of CIP,which is conducive to the early diagnosis and timely treatment of CIP.Therefore,this paper reviews the research progress on risk factors and management strategies of CIP,in order to improve the clinicians' understanding of this adverse event.